Nicholas Blondin, MD
Assistant Professor
Biography
Research & Publications
Patient Care
News
Locations
Appointments
Biography
Nicholas A. Blondin, MD, is Assistant Professor of Clinical Neurology at Yale School of Medicine. Dr. Blondin cares for patients at Smilow Cancer Hospital in New Haven and the Smilow Cancer Hospital Cancer Care Center in Trumbull. He received his Medical Degree from the University of Connecticut School of Medicine and completed his neurology residency at Yale New Haven Hospital, where he was Chief Resident in Neurology, followed by a fellowship in Neuro-Oncology at Yale New Haven Hospital. Before joining Smilow, he was the Director of the Neuro-Oncology Program at Associated Neurologists of Southern CT and the Medical Director of the St. Vincent’s Brain Tumor Center. Watch a video with Dr. Nicholas Blondin>>
Dr. Blondin’s clinical expertise is in treating benign and malignant brain tumors, brain and spine metastasis, and neurological symptoms of cancer, such as seizures, cognitive impairment, headaches, gait disturbance, and weakness. Dr. Blondin is an active investigator for clinical trials for brain tumor patients through Yale Cancer Center.
Education & Training
- Chief ResidentYale School of Medicine (2012)
- ResidentYale School of Medicine (2011)
- InternYale School of Medicine (2009)
- MDUniversity of Connecticut School of Medicine
- BAWesleyan University, Chemistry
Activities
- Integrating Modern Modalities and Systemic Therapies in the Management of GlioblastomaBoston, MA, United States 2021Integrating Modern Modalities and Systemic Therapies in the Management of Glioblastoma
- Observations of Complementary Cannabis Therapy in Malignant Glioma PatientsBoston, MA, United States 2021Observations of Complementary Cannabis Therapy in Malignant Glioma Patients
- Type of Bony Involvement Predicts Genomic Subgroup in Sphenoid Wing MeningiomasBoston, MA, United States 2021Type of Bony Involvement Predicts Genomic Subgroup in Sphenoid Wing Meningiomas
- Surgical Strategies for Older Patients with GlioblastomaBoston, MA, United States 2021Surgical Strategies for Older Patients with Glioblastoma
- Case Series of Multi-Institutional Utility of CNSide to Manage Leptomeningeal Disease in Patients With Metastatic Breast CancerBoston, MA, United States 2021Case Series of Multi-Institutional Utility of CNSide to Manage Leptomeningeal Disease in Patients With Metastatic Breast Cancer
- TTFields Treatment of Gliosarcoma and Recurrent Anaplastic OligodendrogliomaBoston, MA, United States 2021TTFields Treatment of Gliosarcoma and Recurrent Anaplastic Oligodendroglioma
- XCELSIOR: A Real-Time, Real-World Learning Platform for Patients with Advanced CancerBoston, MA, United States 2021XCELSIOR: A Real-Time, Real-World Learning Platform for Patients with Advanced Cancer
- Glioblastoma and Facebook: An Analysis of Perceived Etiologies and TreatmentsPhoenix, AZ, United States 2019Glioblastoma and Facebook: An Analysis of Perceived Etiologies and Treatments
- Feasibility Study of the Emulate Therapeutics Voyager System in Patients with Newly Diagnosed GlioblastomaPhoenix, AZ, United States 2019Feasibility Study of the Emulate Therapeutics Voyager System in Patients with Newly Diagnosed Glioblastoma
- Feasibility Study of the Emulate Therapeutics Voyager System in Patients with Recurrent Glioblastoma (GBM)Phoenix, AZ, United States 2019Feasibility Study of the Emulate Therapeutics Voyager System in Patients with Recurrent Glioblastoma (GBM)
- The Evolving Role of Complementary Cannabis Therapy in Glioblastoma TreatmentNew Orleans, LA, United States 2018The Evolving Role of Complementary Cannabis Therapy in Glioblastoma Treatment
- A Feasibility Study of the Nativis Voyager System in Patients with Newly Diagnosed Glioblastoma (GBM)New Orleans, LA, United States 2018A Feasibility Study of the Nativis Voyager System in Patients with Newly Diagnosed Glioblastoma (GBM)
- The Challenge of Health Utility Values for Glioblastoma Patients with Long-Term SurvivalNew Orleans, LA, United States 2018The Challenge of Health Utility Values for Glioblastoma Patients with Long-Term Survival
- The Effect of Tumor Treating Fields in WHO Grade 2 and 3 GliomasSan Francisco, CA, United States 2017The Effect of Tumor Treating Fields in WHO Grade 2 and 3 Gliomas
- Complementary Cannabis Therapy for Malignant Glioma: Initial ExperienceSan Francisco, CA, United States 2017Complementary Cannabis Therapy for Malignant Glioma: Initial Experience
- Vismodegib Treatment of Intracranial Invasion of Basal Cell CarcinomaSan Francisco, CA, United States 2017Vismodegib Treatment of Intracranial Invasion of Basal Cell Carcinoma
- Determining the Presence of Human Cytomegalovirus Proteins in GlioblastomaSan Francisco, CA, United States 2017Determining the Presence of Human Cytomegalovirus Proteins in Glioblastoma
- Generational Variance in Phenotypic Expression of Autosomal Dominant Spinal Muscular Atrophy Due to BICD2 MutationBoston, MA, United States 2017Generational Variance in Phenotypic Expression of Autosomal Dominant Spinal Muscular Atrophy Due to BICD2 Mutation
- Vismodegib Treatment of Intracranial Invasion of Basal Cell CarcinomaBoston, MA, United States 2017Vismodegib Treatment of Intracranial Invasion of Basal Cell Carcinoma
- Beneficial Effect of Tumor Treating Field Therapy in Diffuse Astrocytoma with Gliomatosis CerebriScottsdale, AZ, United States 2016Beneficial Effect of Tumor Treating Field Therapy in Diffuse Astrocytoma with Gliomatosis Cerebri
- Management of Gliomatosis Cerebri with Temozolomide and Tumor Treating FieldsSan Antonio, TX, United States 2015Management of Gliomatosis Cerebri with Temozolomide and Tumor Treating Fields
- Implementation and Utilization of Genomic Profiling in a Community Neuro-Oncology PracticeSan Antonio, TX, United States 2015Implementation and Utilization of Genomic Profiling in a Community Neuro-Oncology Practice
- Maternally inherited diabetes and deafness (MIDD) syndrome associated with myoclonusNew Orleans, LA, United States 2012Maternally inherited diabetes and deafness (MIDD) syndrome associated with myoclonus
- Leptomeningeal Carcinomatosis associated with Squamous Cell CarcinomaAnaheim, CA, United States 2011Leptomeningeal Carcinomatosis associated with Squamous Cell Carcinoma
- SIADH mimicking limbic encephalitis due to a neuroendocrinetumor with Merkel cell carcinoma phenotypeHonolulu, HI, United States 2011SIADH mimicking limbic encephalitis due to a neuroendocrinetumor with Merkel cell carcinoma phenotype
- Acquired Periodic Hypothermia due to Ischemic StrokeHonolulu, HI, United States 2011Acquired Periodic Hypothermia due to Ischemic Stroke
- T-cell receptor-gamma subunit gene rearrangement analysis in primary meningeal T-cell Non-Hodgkin lymphomaMontreal, QC, Canada 2010T-cell receptor-gamma subunit gene rearrangement analysis in primary meningeal T-cell Non-Hodgkin lymphoma
Honors & Recognition
| Award | Awarding Organization | Date |
|---|---|---|
| Connecticut Brain Tumor Alliance Humanitarian Award | Connecticut Brain Tumor Alliance | 2018 |
| Cigna Care Designation | Cigna | 2017 |
| UnitedHealth Premium Designation, Quality & Cost Efficiency | UnitedHealthcare | 2017 |
| Palatucci Advocacy Leadership Forum Graduate | American Academy of Neurology | 2014 |
| Gold Humanism Honor Society | Yale School of Medicine | 2013 |
| Betsy Winters House Staff Award | Yale School of Medicine | 2012 |
| Power Day II Resident Award | Yale School of Medicine | 2012 |
| Lewis L. Levy Award in Neurology | Yale School of Medicine | 2010 |
| Power Day II Resident Award | Yale School of Medicine | 2010 |
| Schwartz Award | University of Connecticut School of Medicine | 2007 |
| Cardinal Health Research Award | University of Connecticut School of Medicine | 2006 |
| Abbott Laboratories Research Award | University of Connecticut School of Medicine | 2005 |
| Butterfield Prize | Wesleyan University | 2004 |
| Bradley Prize | Wesleyan University | 2004 |
| Phi Beta Kappa | Wesleyan University | 2004 |
| Honors in Chemistry | Wesleyan University | 2004 |
| American Institute of Chemists Award | Wesleyan University | 2004 |
| Howard Hughes Summer Research Fellowship | Wesleyan University | 2003 |
| American Chemical Society Analytical Award | Wesleyan University | 2003 |
| Bristol-Myers Squibb Student Research Fellowship | Wesleyan University | 2002 |
| Valedictorian and Senior Class President | Litchfield High School | 2000 |
Professional Service
| Organization | Role | Date |
|---|---|---|
| Yale University Protocol Review Committee (PRC) | Committee Member | 2022 - Present |
| Society for Neuro-Oncology | Peer reviewer for SNO Annual Meeting | 2020 - Present |
| Cancer Commons | Brain Cancer Advisory Board member, Cancer Commons | 2020 - Present |
| Third Year Neurology Clerkship | Instructor of Third Year Neurology Clerkship, Yale School of Medicine | 2019 - Present |
| National Brain Tumor Society | Head To The Hill, Advocate | 2018 - Present |
| TS Alliance | Professional Advisory Board member, TS Alliance | 2017 - 2018 |
| Musella Foundation | Medical Advisory Board member, Musella Foundation | 2017 - Present |
| St. Vincent's Brain Tumor Research Fund | Director of the St. Vincent's Brain Tumor Center Research Fund, with funding provided by the Connecticut Brain Tumor Alliance and individual donations | 2015 - 2018 |
| Swim Across The Sound | Participant in the St. Vincent's Swim Across The Sound marathon | 2015 - Present |
| Connecticut Brain Tumor Alliance | Medical Board member, Connecticut Brain Tumor Alliance | 2014 - Present |
| Society for Neuro-Oncology | Member | 2013 - Present |
| American Society of Clinical Oncology | Member | 2013 - Present |
| American Academy of Neurology | Member | 2009 - Present |